Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of HKGM-453 in primary hypertension inadequately controlled by amlodipine or sacubitril/valsartan monotherapy
CTR20263243Phase 3Active
- Sponsor
- Yidahong Pharmaceutical
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of allisartan isoproxil in essential hypertension, sponsored by Yidahong Pharmaceutical. Started Sep 2026; status: active.
02
Drugs
allisartan isoproxil
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20263243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263243.